Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

9.080 +0.030 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Crude Oil Surges 2%; Chicago Fed National Activity Index Edges Lower in July
 
Via Benzinga
Topics Economy
Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact
Via Stocktwits
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Insights Ahead: Valneva's Quarterly Earnings
 
Via Benzinga
4 Analysts Have This To Say About Valneva
 
Via Benzinga
Expert Ratings For Valneva
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
 
Via Benzinga
Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US
Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sales and regulatory review. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Valneva
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
MP Materials, CoreWeave, Trade Desk And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026
Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026. 
Via Benzinga
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment. 
Via Benzinga
Topics Death
12 Analysts Assess Valneva: What You Need To Know
 
Via Benzinga
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions. 
Via Benzinga
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Breaking Down Valneva: 6 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For March 20, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions. 
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.